Experimental malaria monoclonal antibody protective in Malian children

One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial. The trial assessed an investigational monoclonal antibody developed by scientists at the National Institutes of Health (NIH), and results appear in The New England Journal of Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup